LLY ▼ -1.4% - Eli Lilly and Company $LLY - Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis 19-OCT-2026 04:40 AM ET